AgingResearch.NewsJoin free

Phase 1Recruiting

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage)

A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)

Sponsor
Caribou Biosciences, Inc. (Industry)
Enrolment
50 planned
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
CB-011
Ages
adults, older adults
Registry
NCT05722418

Full record on ClinicalTrials.gov

From the registry

This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).

Primary outcomes

  • (Part A) Number of patients with dose limiting toxicities (DLT)
  • (Part B) Overall Response Rate (ORR)

History

  1. Primary completion expected

  2. Last registry update

  3. Registered

  4. Started